166 related articles for article (PubMed ID: 35805938)
1. Seventy-Two-Hour LRRK2 Kinase Activity Inhibition Increases Lysosomal GBA Expression in H4, a Human Neuroglioma Cell Line.
Ruz C; Alcantud JL; Vives F; Arrebola F; Hardy J; Lewis PA; Manzoni C; Duran R
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805938
[TBL] [Abstract][Full Text] [Related]
2. LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson's disease.
Pang SY; Lo RCN; Ho PW; Liu HF; Chang EES; Leung CT; Malki Y; Choi ZY; Wong WY; Kung MH; Ramsden DB; Ho SL
Transl Neurodegener; 2022 Jan; 11(1):5. PubMed ID: 35101134
[TBL] [Abstract][Full Text] [Related]
3. The Effect of p.G2019S Mutation in the
Usenko TS; Timofeeva A; Beletskaia M; Basharova K; Baydakova G; Bezrukova A; Grunina M; Emelyanov A; Miliukhina I; Zakharova E; Pchelina S
J Integr Neurosci; 2024 Jan; 23(1):16. PubMed ID: 38287861
[TBL] [Abstract][Full Text] [Related]
4. Glucocerebrosidase 1 and leucine-rich repeat kinase 2 in Parkinson disease and interplay between the two genes.
Lee CY; Menozzi E; Chau KY; Schapira AHV
J Neurochem; 2021 Dec; 159(5):826-839. PubMed ID: 34618942
[TBL] [Abstract][Full Text] [Related]
5. Constitutive silencing of LRRK2 kinase activity leads to early glucocerebrosidase deregulation and late impairment of autophagy in vivo.
Albanese F; Mercatelli D; Finetti L; Lamonaca G; Pizzi S; Shimshek DR; Bernacchia G; Morari M
Neurobiol Dis; 2021 Nov; 159():105487. PubMed ID: 34419621
[TBL] [Abstract][Full Text] [Related]
6. LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson's disease patients.
Ysselstein D; Nguyen M; Young TJ; Severino A; Schwake M; Merchant K; Krainc D
Nat Commun; 2019 Dec; 10(1):5570. PubMed ID: 31804465
[TBL] [Abstract][Full Text] [Related]
7. Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity.
Omer N; Giladi N; Gurevich T; Bar-Shira A; Gana-Weisz M; Glinka T; Goldstein O; Kestenbaum M; Cedarbaum JM; Mabrouk OS; Fraser KB; Shirvan JC; Orr-Urtreger A; Mirelman A; Thaler A
Mov Disord; 2022 Jan; 37(1):190-195. PubMed ID: 34550621
[TBL] [Abstract][Full Text] [Related]
8. Lysosomal Pathogenesis of Parkinson's Disease: Insights From LRRK2 and GBA1 Rodent Models.
Volta M
Neurotherapeutics; 2023 Jan; 20(1):127-139. PubMed ID: 36085537
[TBL] [Abstract][Full Text] [Related]
9. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.
Alcalay RN; Levy OA; Waters CC; Fahn S; Ford B; Kuo SH; Mazzoni P; Pauciulo MW; Nichols WC; Gan-Or Z; Rouleau GA; Chung WK; Wolf P; Oliva P; Keutzer J; Marder K; Zhang X
Brain; 2015 Sep; 138(Pt 9):2648-58. PubMed ID: 26117366
[TBL] [Abstract][Full Text] [Related]
10. Alpha galactosidase A activity in Parkinson's disease.
Alcalay RN; Wolf P; Levy OA; Kang UJ; Waters C; Fahn S; Ford B; Kuo SH; Vanegas N; Shah H; Liong C; Narayan S; Pauciulo MW; Nichols WC; Gan-Or Z; Rouleau GA; Chung WK; Oliva P; Keutzer J; Marder K; Zhang XK
Neurobiol Dis; 2018 Apr; 112():85-90. PubMed ID: 29369793
[TBL] [Abstract][Full Text] [Related]
11. LRRK2 and GBA Variants Exert Distinct Influences on Parkinson's Disease-Specific Metabolic Networks.
Schindlbeck KA; Vo A; Nguyen N; Tang CC; Niethammer M; Dhawan V; Brandt V; Saunders-Pullman R; Bressman SB; Eidelberg D
Cereb Cortex; 2020 May; 30(5):2867-2878. PubMed ID: 31813991
[TBL] [Abstract][Full Text] [Related]
12. Rotenone Blocks the Glucocerebrosidase Enzyme and Induces the Accumulation of Lysosomes and Autophagolysosomes Independently of LRRK2 Kinase in HEK-293 Cells.
Perez-Abshana LP; Mendivil-Perez M; Velez-Pardo C; Jimenez-Del-Rio M
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445771
[TBL] [Abstract][Full Text] [Related]
13. LRRK2 exonic variants are associated with lysosomal hydrolase activities and lysosphingolipid alterations in Parkinson's disease.
Usenko TS; Senkevich KA; Basharova KS; Bezrukova AI; Baydakova GV; Tyurin AA; Beletskaya MV; Kulabukhova DG; Grunina MN; Emelyanov AK; Miliukhina IV; Timofeeva AA; Zakharova EY; Pchelina SN
Gene; 2023 Oct; 882():147639. PubMed ID: 37473971
[TBL] [Abstract][Full Text] [Related]
14. Experimental studies of mitochondrial and lysosomal function in in vitro and in vivo models relevant to Parkinson's disease genetic risk.
Thomas R; Hallett PJ; Isacson O
Int Rev Neurobiol; 2020; 154():279-302. PubMed ID: 32739007
[TBL] [Abstract][Full Text] [Related]
15. Lysosome and Inflammatory Defects in GBA1-Mutant Astrocytes Are Normalized by LRRK2 Inhibition.
Sanyal A; DeAndrade MP; Novis HS; Lin S; Chang J; Lengacher N; Tomlinson JJ; Tansey MG; LaVoie MJ
Mov Disord; 2020 May; 35(5):760-773. PubMed ID: 32034799
[TBL] [Abstract][Full Text] [Related]
16. LRRK2 p.M1646T is associated with glucocerebrosidase activity and with Parkinson's disease.
Sosero YL; Yu E; Krohn L; Rudakou U; Mufti K; Ruskey JA; Asayesh F; Laurent SB; Spiegelman D; Fahn S; Waters C; Sardi SP; Bandres-Ciga S; Alcalay RN; Gan-Or Z; Senkevich K
Neurobiol Aging; 2021 Jul; 103():142.e1-142.e5. PubMed ID: 33781610
[TBL] [Abstract][Full Text] [Related]
17. Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.
Simuni T; Brumm MC; Uribe L; Caspell-Garcia C; Coffey CS; Siderowf A; Alcalay RN; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Nudelman K; Tosun-Turgut D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten S; Bressman S; Marek K;
Mov Disord; 2020 May; 35(5):833-844. PubMed ID: 32073681
[TBL] [Abstract][Full Text] [Related]
18. Modulation of β-glucocerebrosidase increases α-synuclein secretion and exosome release in mouse models of Parkinson's disease.
Papadopoulos VE; Nikolopoulou G; Antoniadou I; Karachaliou A; Arianoglou G; Emmanouilidou E; Sardi SP; Stefanis L; Vekrellis K
Hum Mol Genet; 2018 May; 27(10):1696-1710. PubMed ID: 29547959
[TBL] [Abstract][Full Text] [Related]
19. Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α-synuclein in neurons.
Schapansky J; Khasnavis S; DeAndrade MP; Nardozzi JD; Falkson SR; Boyd JD; Sanderson JB; Bartels T; Melrose HL; LaVoie MJ
Neurobiol Dis; 2018 Mar; 111():26-35. PubMed ID: 29246723
[TBL] [Abstract][Full Text] [Related]
20. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]